HIGHLIGHTS
- who: Juan Huang from the The University of Arizona, United States have published the paper: Clinical antidiabetic medication used in Alzheimer`s disease: From basic discovery to therapeutics development, in the Journal: (JOURNAL)
- what: The authors believe that this is not consistent with the selection and analysis goals of data.
SUMMARY
In recent years, some progress has been made in anti-AD drugs, such as the Aducanumab approved by United_States Federal Drug Administration (FDA), GV-971 approved by the National Medical Products Administration (NMPA), and Lecanemab, an initial decision on the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.